FlexTrade Implements Machine Learning for Real-time Market Impact Analytics
11.5.2022 11:14:00 EEST | Business Wire | Press release
FlexTrade Systems, a global leader in multi-asset execution and order management systems, today announced the launch of machine-learning driven real-time market impact analytics, which are now available within FlexTRADER EMS.
This analytics enhancement comes as the industry calls for solutions providers to increase innovation and deliver actionable analytics to help improve decision-making and reduce market impact on the buy-side trading desk. FlexTrade's in-house data science team has driven the new initiative and refined it further through input and collaboration with clients.
FlexTrade's market impact analytics are generated by applying a proprietary neural network model to a large corpus of order data to help investment managers understand the performance of their execution strategies. The solution allows traders to see an estimate of their current and realized market impact in real-time, meaning strategies can be monitored and adjusted automatically based on market conditions. Traders using the solution can also leverage data visualization to understand how the market impact has changed over the life of the order, including any increases or decreases as more volume is traded or when an order is finished or paused. Further, the new offering, deeply integrated directly within the FlexTRADER EMS order blotter, can be viewed holistically alongside third-party analytics to deliver increased transparency, improved trading decision-making and assist with best execution obligations.
FlexTrade's real-time machine-learning driven market impact analytics are available immediately for deployment, with the first client, an EMEA based Tier 1 buy-side asset manager, live in production. FlexTrade will showcase the new analytics offering this month at WBR's TradeTech Europe in Paris on the 11th and 12th of May.
Andy Mahoney, Managing Director, EMEA at FlexTrade, noted : "Designing and delivering ground-breaking innovation is at the core of what we do at FlexTrade. Leveraging new technologies such as machine learning ensures FlexTrade's clients can take advantage of unique, actionable insights to drive their trading in real-time. At a time when the industry is calling for innovation to return following a lull, understandably, caused by the pandemic, we are at the front of the pack offering disruptive technologies led initiatives - rapidly delivered to the market and our clients - that add real tangible value to their execution strategies."
About FlexTrade
Founded in 1996, FlexTrade Systems is the global leader in high performance execution management and order management systems for equities, foreign exchange, options, futures, and fixed income.
A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER, the world's first broker-neutral, and execution management trading system, which allows clients to completely control and customize their proprietary algorithms while maintaining the confidentiality of their trading strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006410/en/
Contact information
Iain Smith
Iain.Smith@FlexTrade.com
o: +44 20 3757 9311 x 9311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 16:15:00 EEST | Press release
OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leading AI providers, including Anthropic, Google, OpenAI, xAI, and DeepSeek, among others. The platform is used by over 8 million global users, including AI-native startups and large enterprises,
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 16:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in markets traditional channels can't reach. Each operates at the center of how games are discovered, adopted, an
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 15:00:00 EEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 15:00:00 EEST | Press release
ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful innovation to patients through technologies that advance precision, safety, and the overall treatment experience,” said Sheraz Daya, MD, Medical Director and Founder of Centre for Sight. “We are proud to be the first center globally
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 15:00:00 EEST | Press release
BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures and HEPATOMUNE® tri-cultures. Additionally, Christian Smith, Scientist I, R&D at BioIVT will present a poster titled "Therapeutic Reversal of Established Steatosis Usin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom